期刊
NATURE REVIEWS DRUG DISCOVERY
卷 12, 期 5, 页码 359-370出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3979
关键词
-
资金
- Pelotonia, the American Cancer Society [MRSG-12-194-01]
- Landon-Foundation AACR Innovator Award for Personalized Cancer Medicine
- Prostate Cancer Foundation
The recent surge in high-throughput sequencing of cancer genomes has supported an expanding molecular classification of cancer. These studies have identified putative predictive biomarkers signifying aberrant oncogene pathway activation and may provide a rationale for matching patients with molecularly targeted therapies in clinical trials. Here, we discuss some of the challenges of adapting these data for rare cancers or molecular subsets of certain cancers, which will require aligning the availability of investigational agents, rapid turnaround of clinical grade sequencing, molecular eligibility and reconsidering clinical trial design and end points.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据